Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEMKT:IGC OTCMKTS:IMUC NASDAQ:SCYX NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGCIGC Pharma$0.36+9.5%$0.34$0.25▼$0.48$33.74M1.48913,992 shs214,616 shsIMUCEOM Pharmaceutical$0.09-9.7%$0.09$0.01▼$0.21$12.57M-0.012,342 shs8,410 shsSCYXSCYNEXIS$0.81-0.7%$0.75$0.66▼$1.78$34.38M1.64190,870 shs32,864 shsSNYRSynergy CHC$2.90+1.4%$3.22$1.19▼$10.00$26.96MN/A51,274 shs31,014 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGCIGC Pharma-2.69%+0.84%-0.82%+7.42%-6.68%IMUCEOM Pharmaceutical+38.06%+47.70%+27.44%-7.96%-33.29%SCYXSCYNEXIS+3.80%-2.97%+15.25%+6.51%-53.67%SNYRSynergy CHC-12.80%-25.91%-18.29%+40.20%+9,433.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGCIGC Pharma1.8165 of 5 stars3.50.00.00.01.71.70.0IMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ASCYXSCYNEXIS0.9053 of 5 stars0.05.00.00.00.90.80.6SNYRSynergy CHC4.349 of 5 stars3.80.00.00.02.93.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGCIGC Pharma 3.00Buy$3.88985.43% UpsideIMUCEOM Pharmaceutical 0.00N/AN/AN/ASCYXSCYNEXIS 0.00N/AN/AN/ASNYRSynergy CHC 3.50Strong Buy$10.00244.83% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGCIGC Pharma$1.33M24.43N/AN/A$0.08 per share4.46IMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/ASCYXSCYNEXIS$3.75M9.10N/AN/A$1.06 per share0.77SNYRSynergy CHC$34.83M0.79$0.27 per share10.73($1.31) per share-2.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGCIGC Pharma-$13M-$0.07N/AN/AN/A-714.16%-122.44%-88.40%N/AIMUCEOM Pharmaceutical-$1.89MN/A0.00∞N/AN/AN/AN/AN/ASCYXSCYNEXIS-$21.29M-$0.40N/A16.29N/A-599.05%-43.04%-28.21%11/5/2025 (Estimated)SNYRSynergy CHC$2.12M$0.387.634.92N/A10.02%-18.56%20.28%N/ALatest IMUC, SCYX, SNYR, and IGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SNYRSynergy CHC$0.08$0.17+$0.09$0.17$10.80 million$6.74 million8/13/2025Q2 2025SCYXSCYNEXIS-$0.23-$0.14+$0.09-$0.14$0.15 million$1.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGCIGC PharmaN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGCIGC Pharma0.021.150.98IMUCEOM PharmaceuticalN/AN/AN/ASCYXSCYNEXISN/A5.205.20SNYRSynergy CHCN/A2.741.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGCIGC Pharma3.87%IMUCEOM PharmaceuticalN/ASCYXSCYNEXIS54.37%SNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipIGCIGC Pharma31.48%IMUCEOM Pharmaceutical3.28%SCYXSCYNEXIS4.86%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGCIGC Pharma6190.81 million54.60 millionN/AIMUCEOM Pharmaceutical3126.50 million122.35 millionNot OptionableSCYXSCYNEXIS6041.92 million39.89 millionOptionableSNYRSynergy CHC409.44 million4.10 millionN/AIMUC, SCYX, SNYR, and IGC HeadlinesRecent News About These CompaniesSynergy CHC Corp to Present at the 2025 Gateway Conference on September 4thAugust 21 at 9:40 AM | markets.businessinsider.comNew to The Street’s Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S ...August 20 at 6:38 PM | palmbeachpost.comPSynergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + EnergyAugust 18 at 1:09 PM | taiwannews.com.twTNew to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...August 18 at 1:09 PM | finanznachrichten.deSynergy CHC announces major distribution with for FOCUSfactor Focus + EnergyAugust 18 at 1:09 PM | msn.comSynergy CHC Expands FOCUSfactor Distribution with EG AmericaAugust 18 at 9:59 AM | tipranks.comAnalysts Set Expectations for Synergy CHC FY2025 EarningsAugust 18 at 3:01 AM | americanbankingnews.comSynergy CHC files to sell 1.28M shares of common stockAugust 15, 2025 | msn.comSynergy Chc EPS Jumps 86 Percent in Q2August 15, 2025 | theglobeandmail.comSynergy CHC Corp.: Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of ProfitabilityAugust 14, 2025 | finanznachrichten.deSynergy CHC reports Q2 EPS 17c vs 9c last yearAugust 14, 2025 | msn.comSynergy CHC Corp. Reports Strong Second Quarter 2025 Financial Results with Significant Year-over-Year GrowthAugust 14, 2025 | quiverquant.comQSynergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of ProfitabilityAugust 14, 2025 | globenewswire.comHead-To-Head Contrast: Synergy CHC (NASDAQ:SNYR) vs. Krispy Kreme (NASDAQ:DNUT)August 10, 2025 | americanbankingnews.comNew to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion RateAugust 5, 2025 | indystar.comINew to The Street Launches 1,000+ Commercial TV Blitz for Synergy CHC ($SNYR), Makers of Focus Factor(R) – Adds NewsOut Video PR Coverage & NYC #1 Market SaturationAugust 5, 2025 | desmoinesregister.comDJack Ross Buys Handful Of Shares In Synergy CHCAugust 3, 2025 | finance.yahoo.comInsider Buying: Synergy CHC Corp. (NASDAQ:SNYR) CEO Purchases 3,750 Shares of StockAugust 1, 2025 | insidertrades.comSynergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call InformationJuly 31, 2025 | manilatimes.netMSynergy CHC Corp. Stock (SNYR) Opinions on Retail Distribution ExpansionJuly 31, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUC, SCYX, SNYR, and IGC Company DescriptionsIGC Pharma NYSEMKT:IGC$0.36 +0.03 (+9.48%) Closing price 03:59 PM EasternExtended Trading$0.36 +0.00 (+0.28%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.EOM Pharmaceutical OTCMKTS:IMUC$0.09 -0.01 (-9.66%) As of 02:45 PM EasternImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.SCYNEXIS NASDAQ:SCYX$0.81 -0.01 (-0.70%) Closing price 03:50 PM EasternExtended Trading$0.81 0.00 (-0.41%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Synergy CHC NASDAQ:SNYR$2.90 +0.04 (+1.40%) As of 03:59 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access